Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis

摘要: Cabergoline is a recommended first-line dopamine agonist for prolactinoma treatment, which withdrawable some cases. However, the optimal withdrawal strategy and accurate recurrence rate associated with cabergoline remains uncertain. To assess current of hyperprolactinemia possible favorable factors in patients. The databases PubMed, EMBASE, Web Science were searched up to May 2014 identify studies containing data recurrent patients after withdrawal. Meta-analysis, including sensitivity analysis, meta-regression subgroup analysis performed. When who received pooled, it was found that 65 % by random effects meta-analysis [95 % confidence interval 55–74 %]. In adjusting strategies, CAB dose reduced lowest level before treatment success (p = 0.006), whereas longer than 2 years showed no trend effect (p = 0.587). Patients presented significant reduction tumor size more likely achieve best (p < 0.001). Our shows recurs majority probability favors have achieved normoprolactinemia considerable low treatment. addition, our study further suggests beneficial tapering but not duration 2 years.